Alkermes Trades Tightly, Holds In Buying Range
Alkermes (ALKS) has scored big gains so far in 2013, but it continues to hang in a possible buying range. The Ireland-headquartered biotech is a turnaround story, just like Regeneron (REGN), a biotech featured in this column for Thursday's IBD. As noted in a Sept. 18 New America article, Alkermes has made an impressive comeback from its unprofitable years thanks to a 2011 merger with Elan Drug Technologies, the drug formulation and manufacturing
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here